Personalized vaccine shows promise for pancreatic cancer patients

sciencealert.com

An experimental personalized mRNA vaccine shows promise for pancreatic cancer, with seven patients alive six years later. The vaccine, tailored to individual tumors, helps the immune system recognize and fight cancer cells. This approach is part of a phase 1 clinical trial. Pancreatic cancer has a very low survival rate, and this vaccine is being tested in patients with operable tumors following surgery and other treatments.


With a significance score of 5.7, this news ranks in the top 0.6% of today's 33136 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: